In the News
Viral safety testing: Keeping the fly out of the ointment
PPD’s Panteli Theocharous and Patrick Bennett comment on the evolving nature of gene therapies.
The importance of CROs during the pandemic
PPD instrumental in the success of Moderna’s COVID-19 vaccine study
The NC company winning praise with Moderna’s positive Covid vaccine data
PPD recognized for its role in the development of the important vaccine.
PPD lands praise from partner Moderna which reports strong results for COVID-19 vaccine
PPD’s 25 years of vaccine development experience essential to the successful execution of the study.
Training Isn’t a Drive-Thru
Amy Chapman explains that responding to a training request doesn’t need to be treated like a fast food order.
Advanced therapies: Navigation and application of EU and U.S. guidelines during product development
Kirsten Messmer and Richard Dennett provide a high-level overview and navigation guide through the multitude of available advanced therapy guidance in the EU and U.S.
Viral Vector API Characterization of Product-Related Impurities
A team of PPD® Laboratories scientists reviews existing analytical applications, focusing on viral vector characterization of impurities.
PPD’s roles in COVID-19 work continue with milestones
PPD is partnering with various pharma companies to develop treatments and vaccines for the coronavirus.
PPD expands in China with new multifunctional clinical research lab in Suzhou
The new operation will offer bioanalytical, biomarker and vaccine sciences services for global and China-based biopharma customers.
